New Drug Shows 50% Response Rate in Ovarian Cancer Trial

Women facing one of the toughest cancer diagnoses just got a powerful reason for hope.

An experimental drug called QLS5132 helped more than half of patients with advanced platinum-resistant ovarian cancer see their tumors respond, according to results presented at the American Association for Cancer Research Annual Meeting in April 2026. For women with this aggressive form of cancer who had already tried standard treatments without success, these results represent a meaningful breakthrough.

The trial tested 28 patients with a median age of 57.5, all of whom had seen their disease progress despite previous treatments. Platinum-resistant ovarian cancer has historically offered patients few options and poor outcomes, making any effective new treatment particularly significant.

QLS5132 works as an antibody-drug conjugate, essentially a smart missile that targets a protein called CLDN6 found on ovarian cancer cell surfaces. The drug combines a targeted antibody with a cell-killing payload, delivering treatment directly to cancer cells while largely sparing healthy tissue.

The results exceeded expectations. Nine patients achieved partial responses at various dose levels, with 18 evaluable patients showing a 50% objective response rate overall. At higher doses, that rate climbed to 52.9%, with a remarkable 100% disease control rate.

Perhaps most intriguing: the drug worked even in two patients who had no detectable CLDN6 expression. Researchers believe this may result from what they call a "bystander effect," where the treatment damages nearby cancer cells regardless of target protein levels.

Dr. Tao Zhu, chief physician at Zhejiang Cancer Hospital in China who presented the findings, called the safety profile equally encouraging. While 93% of patients experienced treatment-related side effects like nausea and fatigue, none had to stop treatment. Critically, patients avoided serious complications common with other cancer drugs, including lung disease and severe eye problems.

The Ripple Effect

This single trial could reshape treatment for thousands of women globally. If these early results hold up in larger studies, QLS5132 may become the first effective option for a patient population that has long been underserved by existing therapies.

The fact that the drug appears to work regardless of CLDN6 levels could make it accessible to a broader group of patients than initially expected. That means more women might benefit, not just those whose tumors express high levels of the target protein.

The research team is now planning phase III trials to confirm these findings in larger patient groups. For women living with platinum-resistant ovarian cancer and their families, the wait for those results carries genuine hope for a treatment that works when others have failed.